Calabrese et al. retrospectively analyzed preoperative MRI data from 400 patients with WHO grade 4 glioblastoma or astrocytoma, who underwent resection and genetic testing to assess the status of nine key biomarkers: hotspot mutations of IDH1 or TERT promoter, pathogenic mutations of TP53, PTEN, ATRX, or CDKN2A/B, MGMT promoter methylation, EGFR amplification, and combined aneuploidy of chromosomes 7 and 10. This evidence concerns the gene EGFR and glioblastoma.